Mandate

Vinge has advised Oncopeptides in connection with its rights issue

August 28, 2025

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Louise Nässén, Amanda Sandström and Vilma Henricsson.

Related

Vinge advises DNB Carnegie in connection with a EUR 130 million bond issue to finance Incore Invest’s acquisition of CoreOrchestration

Vinge has advised DNB Carnegie Investment Bank AB (publ), in its capacity as sole bookrunner, in connection with an issue of senior secured bonds of EUR 130 million under a framework of EUR 200 million.
February 16, 2026

Vinge has advised BAE Systems Bofors on the acquisition of Aston Harald Mekaniska Verkstad

BAE Systems is a world-leading defence group with a presence in Sweden through, among others, BAE Systems Bofors in Karlskoga, a supplier of weapon systems, artillery and ammunition. The acquisition is strategically motivated and aims to strengthen the Swedish defence industry's production capacity.
February 12, 2026

Vinge has advised Sertion AB in connection with the acquisition of Svensk Anläggning och Driftteknik AB

Through the acquisition, Sertion takes a further step in its development as a leading international infrastructure and installation group within complex HVAC systems, technical infrastructure, and industrial piping. Svensk Anläggning och Driftteknik AB specializes in certified welding and installation of industrial piping.
February 10, 2026